Telo Genomics Corp.

Biotechnology · VANCOUVER, A1

BiotechnologySEC Form D

Telo Genomics Corp. filed a Form D with the U.S. Securities and Exchange Commission on April 24, 2026, reporting $7,346 raised toward a $19,100 offering.

Incorporated in Canada (Federal Level) and based in VANCOUVER, A1, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Telo Genomics Corp. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • John FarlingerExecutive Officer · Director
  • Sabine MaiDirector · Promoter
  • John PriceExecutive Officer
  • Ron McGlennenDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$10.0MRaised

Senti Biosciences Holdings, Inc.

BiotechnologySouth San Francisco, CA
May 20, 2026View SEC Form D
Telo Genomics Corp. raised $7.3K — SEC Form D